KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Interest & Investment Income (2016 - 2025)

Rigel Pharmaceuticals has reported Interest & Investment Income over the past 16 years, most recently at $1.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 138.12% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $3.7 million, up 75.96%, while the annual FY2025 figure was $3.7 million, 75.96% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $1.2 million at Rigel Pharmaceuticals, up from $1.1 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $1.2 million in Q4 2025 and troughed at $1000.0 in Q1 2021.
  • A 5-year average of $438800.0 and a median of $475500.0 in 2022 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: crashed 99.72% in 2021 and later skyrocketed 2581.25% in 2022.
  • Year by year, Interest & Investment Income stood at $16000.0 in 2021, then skyrocketed by 2581.25% to $429000.0 in 2022, then skyrocketed by 58.04% to $678000.0 in 2023, then fell by 23.01% to $522000.0 in 2024, then skyrocketed by 138.12% to $1.2 million in 2025.
  • Business Quant data shows Interest & Investment Income for RIGL at $1.2 million in Q4 2025, $1.1 million in Q3 2025, and $753000.0 in Q2 2025.